Pharmala Biotech Holdings Inc (MDXXF)

$0.08 0.00 (-5.66%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 355,900
Avg Vol 33,084
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 45%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Pharmala Biotech Holdings Inc., doing business as PharmAla, a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

Industry: Biotechnology
Sector: Healthcare
Website: pharmala.ca
Address:
1055 West Georgia Street, P.O. Box 11117, Vancouver, Canada
TimRegan_WTR
TimRegan_WTR Oct. 24 at 1:25 PM
$MDMA.CSE $MDXXF
0 · Reply
JMAR_WTR
JMAR_WTR Oct. 24 at 1:16 PM
$MDMA.CSE $MDXXF
0 · Reply
research_WTR
research_WTR Oct. 24 at 10:49 AM
Check out Robert Sassoon's recap from his podcast with Nick Kadysh, Founding CEO and President of Toronto-headquartered PharmAla Biotech Inc. (MDMA.CSE) discussing regulatory transparency at the FDA, the global divergence in psychedelic medicine policy, clinical research demand, and PharmAla’s evolving development strategy following the Lykos complete response letter (CRL). Those interested can listen at the links in the full report! https://www.watertowerresearch.com/doc?docID=IR_Neuro_10192025 $MDMA.CSE $MDXXF #PharmAla #Psychedelics #Healthcare #Neuroscience #Depression #Mood #SmallCap #Stocks #Investing
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 22 at 1:10 PM
$MDMA.CSE $MDXXF
0 · Reply
research_WTR
research_WTR Oct. 22 at 10:13 AM
New Podcast: PharmAla Biotech Inc. (MDMA.CSE)’s CEO on Psychedelics, the FDA, and What’s Next In the latest WTR Healthcare Happenings, Nick Kadysh, Founding CEO & President of PharmAla Biotech (OTCQB: MDXXF), joins Tim Gerdeman and Robert Sassoon to unpack: 🔹 The global regulatory landscape for psychedelics, especially MDMA 🔹 The impact of the Lykos Therapeutics FDA Complete Response Letter (CRL) 🔹 PharmAla’s strategic approach to clinical-grade MDMA research, manufacturing, and commercialization Listen now on Apple Podcasts, Spotify, or our website! Apple: https://podcasts.apple.com/us/podcast/pharmala-biotechs-ceo-nick-kadysh-on-psychedelics-the/id1795488592?i=1000732945594 Spotify: https://open.spotify.com/episode/0zE6VBIuisAtd6jBVG7q69?si=4d2c00651f964ab4 Website: https://www.watertowerresearch.com/media-detail/2672/Media Others: https://pod.link/1693448305 #HealthcareHappenings #PharmAla #Psychedelics #FDA $MDMA.CSE $MDXXF #Biotech #MentalHealth #DrugDevelopment #SmallCap #Stocks #Healthcare #Investing #WaterTowerResearch
0 · Reply
theflynews
theflynews Oct. 9 at 3:05 PM
Psychedelic: PharmAla launches portal for MDMA prescribers, therapists - $MDXXF - https://thefly.com/permalinks/entry.php/MDXXFid4210901?17
0 · Reply
LOLROFLMAO
LOLROFLMAO Sep. 3 at 1:38 PM
$MDXXF PharmAla Incorporates Australian Entity for Clinical Research https://pharmala.ca/media/2025/09/pharmala-incorporates-australian-entity-for-clinical-research
0 · Reply
McGuireTO
McGuireTO Aug. 5 at 2:33 PM
$MDMA.CSE $MDXXF Pharmala Biotech has set a new support level and is slowly creeping back to resistance with big bid support and orders chipping away at the key level. I'm anticipating this to get a sympathy run along with $ATAI $MNMD and $CMPS and the chart is tight enough that this can be an explosive move
1 · Reply
McGuireTO
McGuireTO Jul. 29 at 1:21 AM
$MDMA.CSE $MDXXF PharmAla Biotech Getting Very Tight, break is imminent. I have a bullish lean on this given the bullish tailwinds in the sector, the ramping up of bull volume on the weekly chart, and the lower wicks that look like accumulation to me on the monthly timeframe I post regular analysis of the psychedelics sector, please like and follow to make sure you don't miss my next update! Support: 0.090, 0.085 Resistance: 0.110, 0.115 https://www.tradingview.com/chart/MDMA/enhXzeMY-PharmAla-Biotech-Getting-Very-Tight-powerful-break-is-imminent/
0 · Reply
research_WTR
research_WTR Jun. 27 at 11:43 AM
Read Robert Sassoon's recap from his latest biotech podcast with Nick Kadysh, Founding CEO and President of @PharmAlaBiotech (MDMA.CSE). Listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_HealtSpe_06262025_1 $MDMA $MDXXF #Healthcare #Biotech #CNS #SmallCap #Stocks #Investing #WTRSpotlight
0 · Reply
Latest News on MDXXF
No data available.
TimRegan_WTR
TimRegan_WTR Oct. 24 at 1:25 PM
$MDMA.CSE $MDXXF
0 · Reply
JMAR_WTR
JMAR_WTR Oct. 24 at 1:16 PM
$MDMA.CSE $MDXXF
0 · Reply
research_WTR
research_WTR Oct. 24 at 10:49 AM
Check out Robert Sassoon's recap from his podcast with Nick Kadysh, Founding CEO and President of Toronto-headquartered PharmAla Biotech Inc. (MDMA.CSE) discussing regulatory transparency at the FDA, the global divergence in psychedelic medicine policy, clinical research demand, and PharmAla’s evolving development strategy following the Lykos complete response letter (CRL). Those interested can listen at the links in the full report! https://www.watertowerresearch.com/doc?docID=IR_Neuro_10192025 $MDMA.CSE $MDXXF #PharmAla #Psychedelics #Healthcare #Neuroscience #Depression #Mood #SmallCap #Stocks #Investing
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 22 at 1:10 PM
$MDMA.CSE $MDXXF
0 · Reply
research_WTR
research_WTR Oct. 22 at 10:13 AM
New Podcast: PharmAla Biotech Inc. (MDMA.CSE)’s CEO on Psychedelics, the FDA, and What’s Next In the latest WTR Healthcare Happenings, Nick Kadysh, Founding CEO & President of PharmAla Biotech (OTCQB: MDXXF), joins Tim Gerdeman and Robert Sassoon to unpack: 🔹 The global regulatory landscape for psychedelics, especially MDMA 🔹 The impact of the Lykos Therapeutics FDA Complete Response Letter (CRL) 🔹 PharmAla’s strategic approach to clinical-grade MDMA research, manufacturing, and commercialization Listen now on Apple Podcasts, Spotify, or our website! Apple: https://podcasts.apple.com/us/podcast/pharmala-biotechs-ceo-nick-kadysh-on-psychedelics-the/id1795488592?i=1000732945594 Spotify: https://open.spotify.com/episode/0zE6VBIuisAtd6jBVG7q69?si=4d2c00651f964ab4 Website: https://www.watertowerresearch.com/media-detail/2672/Media Others: https://pod.link/1693448305 #HealthcareHappenings #PharmAla #Psychedelics #FDA $MDMA.CSE $MDXXF #Biotech #MentalHealth #DrugDevelopment #SmallCap #Stocks #Healthcare #Investing #WaterTowerResearch
0 · Reply
theflynews
theflynews Oct. 9 at 3:05 PM
Psychedelic: PharmAla launches portal for MDMA prescribers, therapists - $MDXXF - https://thefly.com/permalinks/entry.php/MDXXFid4210901?17
0 · Reply
LOLROFLMAO
LOLROFLMAO Sep. 3 at 1:38 PM
$MDXXF PharmAla Incorporates Australian Entity for Clinical Research https://pharmala.ca/media/2025/09/pharmala-incorporates-australian-entity-for-clinical-research
0 · Reply
McGuireTO
McGuireTO Aug. 5 at 2:33 PM
$MDMA.CSE $MDXXF Pharmala Biotech has set a new support level and is slowly creeping back to resistance with big bid support and orders chipping away at the key level. I'm anticipating this to get a sympathy run along with $ATAI $MNMD and $CMPS and the chart is tight enough that this can be an explosive move
1 · Reply
McGuireTO
McGuireTO Jul. 29 at 1:21 AM
$MDMA.CSE $MDXXF PharmAla Biotech Getting Very Tight, break is imminent. I have a bullish lean on this given the bullish tailwinds in the sector, the ramping up of bull volume on the weekly chart, and the lower wicks that look like accumulation to me on the monthly timeframe I post regular analysis of the psychedelics sector, please like and follow to make sure you don't miss my next update! Support: 0.090, 0.085 Resistance: 0.110, 0.115 https://www.tradingview.com/chart/MDMA/enhXzeMY-PharmAla-Biotech-Getting-Very-Tight-powerful-break-is-imminent/
0 · Reply
research_WTR
research_WTR Jun. 27 at 11:43 AM
Read Robert Sassoon's recap from his latest biotech podcast with Nick Kadysh, Founding CEO and President of @PharmAlaBiotech (MDMA.CSE). Listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_HealtSpe_06262025_1 $MDMA $MDXXF #Healthcare #Biotech #CNS #SmallCap #Stocks #Investing #WTRSpotlight
0 · Reply
taxidriver514
taxidriver514 Apr. 30 at 6:28 PM
$MDXXF $MNMD $CYBN $ATAI 🍄💊🤯🪖
0 · Reply
LOLROFLMAO
LOLROFLMAO Apr. 11 at 4:10 PM
$MDXXF Multiple March news...
0 · Reply
GSpotrock
GSpotrock Jan. 22 at 6:32 PM
$MDXXF how is this flying so far under the radar?
1 · Reply
TopChartz
TopChartz Jan. 15 at 4:51 PM
$MDXXF bullish on this sleeper $PSIL $ATAI $CMPS $CYBN
0 · Reply
trevormiltom
trevormiltom Jan. 3 at 6:00 PM
$TSLA take some loses to $MDXXF or MDMA.CSE
0 · Reply
trevormiltom
trevormiltom Jan. 3 at 5:50 PM
$AISP $MDXXF or MDMA.cse getting primed up for a run
0 · Reply
trevormiltom
trevormiltom Jan. 3 at 5:34 PM
$CVNA best penny stock $MDXXF after this becomes one
0 · Reply
LOLROFLMAO
LOLROFLMAO Nov. 14 at 6:11 PM
$MDXXF PharmAla Reaches Agreement In Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License https://pharmala.ca/media/2024/11/pharmala-reaches-agreement-in-principle-to-supply-mdma-to-clinical-trial-in-exchange-for-full-data-license
0 · Reply
LOLROFLMAO
LOLROFLMAO Nov. 7 at 3:03 PM
$MDXXF PharmAla to supply LaNeo MDMA for Clinical Trial at Yale https://pharmala.ca/media/2024/11/pharmala-to-supply-laneo-mdma-for-clinical-trial-at-yale
0 · Reply
LOLROFLMAO
LOLROFLMAO Oct. 30 at 3:57 AM
$MDXXF PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA Oct 21st, 2024 https://www.otcmarkets.com/stock/MDXXF/news/PharmAla-to-supply-Mt-Sinai-Hospital-with-LaNeo-MDMA?id=456329
0 · Reply
LOLROFLMAO
LOLROFLMAO Oct. 30 at 3:56 AM
$MDXXF PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA https://www.otcmarkets.com/stock/MDXXF/news/PharmAla-to-supply-the-University-of-Texas-San-Antonio-with-novel-dosage-form-of-LaNeo-MDMA?id=455196
0 · Reply